Also from this source


You just read:

Cleveland HeartLab Adds Two Additional Patents to its Extensive Intellectual Property Position for the Myeloperoxidase (MPO) test, a key predictor of Major Cardiac Events

News provided by

Cleveland HeartLab Inc.

03 May, 2017, 13:30 ET